Literature DB >> 19555668

Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination.

David J Anderson1, John Malysz, Jens Halvard Grønlien, Rachid El Kouhen, Monika Håkerud, Caroline Wetterstrand, Clark A Briggs, Murali Gopalakrishnan.   

Abstract

alpha4beta2 neuronal nicotinic receptors (nAChRs) can exist in high and low sensitivity states possibly due to distinct stoichiometries during subunit assembly: (alpha4)(2)(beta2)(3) pentamer (high sensitivity, HS) and (alpha4)(3)(beta2)(2) pentamer (low sensitivity, LS). To determine if there is a linkage between HS or LS states and receptor-mediated responses in brain, we profiled several clinically studied alpha4beta2* nAChR agonists for the displacement of radioligand binding to alpha4beta2 [(3)H]-cytisine sites in rat brain membranes, effects on stimulation of [(3)H]-dopamine release from slices of rat prefrontal cortex and striatum, and activation of HS and LS human alpha4beta2 nAChRs expressed in Xenopus laevis oocytes. Binding affinities (pK(i)) and potency (pEC(50)) values for [(3)H]-dopamine release closely correlated with a rank order: varenicline>(-)-nicotine>AZD3480>dianicline congruent with ABT-089. Further, a good correlation was observed between [(3)H]-dopamine release and HS alpha4beta2 pEC(50) values, but not between [(3)H]-dopamine release and LS alpha4beta2. The relative efficacies of the agonists ranged from full to partial agonists. Varenicline behaved as a partial agonist in stimulating [(3)H]-dopamine release and activating both HS and LS alpha4beta2 nAChRs expressed in oocytes. Conversely, ABT-089, AZD3480 and dianicline exhibited little efficacy at LS alpha4beta2 (<5%), were more effective at HS alpha4beta2 nAChRs, and in stimulating cortical and striatal [(3)H]-dopamine release >or=30%. In the presence of alpha-conotoxin MII to block alpha6beta2* nAChRs, the alpha4beta2* alpha-conotoxin-insensitive [(3)H]-dopamine release stimulated by these ligands correlates well with their interactions at HS, but not LS. In summary, this study provides support for HS alpha4beta2* nAChR involvement in neurotransmitter release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555668     DOI: 10.1016/j.bcp.2009.06.024

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  24 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Prefrontal neuromodulation by nicotinic receptors for cognitive processes.

Authors:  Renata dos Santos Coura; Sylvie Granon
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

Review 4.  Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

Authors:  Dympna Harmey; Patrick R Griffin; Paul J Kenny
Journal:  Nicotine Tob Res       Date:  2012-09-27       Impact factor: 4.244

5.  Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats.

Authors:  Morten Grupe; Giovanna Paolone; Anders A Jensen; Karin Sandager-Nielsen; Martin Sarter; Morten Grunnet
Journal:  Biochem Pharmacol       Date:  2013-09-16       Impact factor: 5.858

6.  Stoichiometry of the Heteromeric Nicotinic Receptors of the Renshaw Cell.

Authors:  Boris Lamotte d'Incamps; Tamara Zorbaz; Dominika Dingova; Eric Krejci; Philippe Ascher
Journal:  J Neurosci       Date:  2018-05-03       Impact factor: 6.167

7.  A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Miguel Alvarez-Estrada; Arthur L Brody
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

8.  Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283.

Authors:  John J Maurer; Karin Sandager-Nielsen; Heath D Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2016-11-14       Impact factor: 4.530

9.  Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.

Authors:  Tanuja Bordia; Maya Hrachova; Matthew Chin; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2012-05-01       Impact factor: 4.030

10.  The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.

Authors:  Danhui Zhang; Matthew McGregor; Michael W Decker; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2014-07-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.